Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

ClinicalTrials.gov ID: NCT02069093

Public ClinicalTrials.gov record NCT02069093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Study identification

NCT ID
NCT02069093
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
92 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2014 (Type not available)
Primary completion
Mar 2016 (Actual)
Completion
Mar 2016 (Actual)
Last update posted
Feb 13, 2017

2014 – 2016

United States locations

U.S. sites
23
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Highlands Oncology Group Highlands Oncology Group (22) Fayetteville Arkansas 72703 —
Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C Anaheim California 92807 —
Los Angeles Hematology/Oncology Medical Group Los Angeles California 90017 —
University of California at Los Angeles UCLA and TRIO Network Los Angeles California 90095-6956 —
University of California Irvine UC Irvine Medical Center Orange California 92868 —
University of California San Francisco UCSF Medical Center San Francisco California 94101 —
California Pacific Medical Center SC San Francisco California 94115 —
University of Connecticut Health Center Farmington Connecticut 06030-3940 —
Southeastern Regional Medical Center Newnan Georgia 30265 —
OnCare Hawaii ‘Aiea Hawaii 96701 —
North Shore University Health System NorthShore University Evanston Illinois 60201 —
Oncology Specialists, SC Onc Specialists Park Ridge Illinois 60068-0736 —
University of Maryland School of Medicine University of Maryland Baltimore Maryland 21201-1559 —
Kaiser Permanente - Mid Atlantic Permanete Research Institut Kaiser Permanente Mid-Atlantic Rockville Maryland 20850 —
Karmanos Cancer Institute Karmanos Cancer Institute (2) Detroit Michigan 48201 —
Saint Luke's Hospital/Marion Bloch Neuroscience Institute Cancer Institute Kansas City Missouri 64111 —
Regional Cancer Care Associates Cancer and Hematologic Disease Cherry Hill New Jersey 08003 —
Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2) Morristown New Jersey 07962 —
M. Francisco Gonzalez, MD.PA Hematology Oncology Center Columbia South Carolina 29203 —
Oncology Consultants Oncology Consultants, P.A. Houston Texas 77024 —
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2) Houston Texas 77030-4009 —
Delta Oncology Associates Delta Hematology/Oncology Portsmouth Virginia 23704 —
Northwest Medical Specialties Northwest Medical - Puyallup Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02069093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 13, 2017 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02069093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →